INKT News and Press, MiNK Therapeutics Inc. From 05/11/23

agenT-797, an allo-iNKT cell therapy, shows clinical responses in heavily pre-treated solid tumor cancers when administered with anti-PD-1 and persists without lymphodepletion. Initiating phase 1/2 expansion studies in NSCLC and gastric cancer, with majority costs planned for external, non-di...

2023-05-10 17:41:46 ET MiNK Therapeutics press release ( NASDAQ: INKT ): Q1 GAAP EPS of -$0.22 beats by $0.02 . Revenue of $22.9M (-11.7% Y/Y). We ended our first quarter 2023 with a cash, cash equivalent and short-term investment balance of $189.2 million, compare...

2023-05-08 10:03:22 ET Gainers: Immuron ( IMRN ) +49% . ANI Pharmaceuticals ( ANIP ) +17% . MiNK Therapeutics ( INKT ) +13% . Evaxion Biotech ( EVAX ) +8% . Predictive Oncology ( POAI ) +8% . Losers: Catalent ( CTLT ) ...

2023-05-04 10:00:25 ET Gainers: Soligenix ( SNGX ) +117% . ZimVie ( ZIMV ) +27% . Lantheus ( LNTH ) +14% . MiNK Therapeutics ( INKT ) +16% . Reviva Pharmaceuticals ( RVPH ) +10% . Losers: Sensus Healthcare ( SRTS ...

2023-05-04 08:50:48 ET Soligenix ( SNGX ) +282% Announces Positive Clinical Results from Compatibility Study of HyBryte in the Treatment of Cutaneous T-Cell Lymphoma. SaverOne  ( SVRE ) +53% Concludes Successful Pilot Demonstration with Abu Dhabi Integrated Tran...

NEW YORK, April 27, 2023 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other imm...

Allogeneic iNKTs, agenT-797, administered alone or in combination with anti-PD-1 therapy, shows activity in patients with refractory solid tumor cancers. In a patient with metastatic gastric cancer who had no response to treatment with pembrolizumab and nivolumab/FOLFOX, agenT-797 induced a p...

2023-04-09 12:00:00 ET The largest meeting in the world of cancer research is set to kick off this week. The annual meeting of the American Association for Cancer Research (AACR) is a much sought-after event in the healthcare calendar, with many pharma companies scheduled to highlight their...

Agenus Inc. (Nasdaq: AGEN), an immuno-oncology company with a pipeline of immunological agents targeting cancer and infectious disease, today announced that its Board of Directors has declared a dividend of 5 million shares of common stock of its subsidiary, MiNK Therapeutics, Inc. (“MiNK&...

2023-03-25 02:17:53 ET Summary AgenT-797 data presented at SITC in November was encouraging. More AgenT-797 cancer data expected at AACR on April 18. But cash is low, so will need to raise more to continue operations. MiNK Therapeutics ( INKT ) was formed in 2021...